Adaptive Biotechnologies (ADPT) reported $277M in revenue for fiscal 2025, +54.8% year on year. That ranks #2522 by revenue among 2853 SEC filers and #254 in Healthcare. It posted a net loss of −$59.5M for the same year. Revenue has grown 28.0% a year on average since 2017 ($38.4M then). The fiscal 2025 balance sheet shows $513M in total assets, $70.5M in cash and $127M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $277M | +54.8% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | −$57.1M | +$105M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$59.5M | +$100.0M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$46.0M | +$49.2M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $3.0M | −19.2% | FY20252025-12-31 |
| Total assetsAssets | $513M | −4.9% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $219M | +7.9% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $70.5M | +47.1% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $127M | −4.4% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $70.9M | −$20.0M | Open → |
| Q2 20262026-06-30 | $71.6M | −$39.8M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Adaptive Biotechnologies Corp
- Ticker
- ADPT
- Exchange
- Nasdaq
- SIC classification
- Biological Products, (No Diagnostic Substances) (2836)
- Fiscal year end
- 12-31
- CIK
- 0001478320
Filings
- 10-QAug 4, 2026Open filing →
- 10-QMay 5, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Rigel PharmaceuticalsRIGL | $294M | $367M |
| Xeris BiopharmaXERS | $292M | $554,000 |
| Aurinia PharmaceuticalsAUPH | $283M | $287M |
| Adaptive BiotechnologiesADPT | $277M | −$59.5M |
| VericelVCEL | $276M | $16.5M |
| HarrowHROW | $272M | −$5.1M |
| Viemed HealthcareVMD | $270M | $15.4M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Adaptive Biotechnologies — Key figures |url=https://companiesranked.com/en/company/adaptive-biotechnologies |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Adaptive Biotechnologies — Key figures. CompaniesRanked. https://companiesranked.com/en/company/adaptive-biotechnologiesBibTeX
@misc{companiesranked-en-company-adaptive-biotechnologies-2026,
author = {{CompaniesRanked}},
title = {{Adaptive Biotechnologies — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/adaptive-biotechnologies}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-076902 · February 26, 2026
{{cite web |title=Adaptive Biotechnologies — Key figures — 10-K (0001193125-26-076902) |url=https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/adpt-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.